Your browser doesn't support javascript.
loading
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
DeZern, Amy E; Greenberg, Peter L.
Affiliation
  • DeZern AE; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
  • Greenberg PL; Hematology Division, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Blood ; 142(26): 2258-2267, 2023 12 28.
Article in En | MEDLINE | ID: mdl-37562001
ABSTRACT: Risk stratification and prognostication are crucial for the appropriate management of patients with myelodysplastic syndromes (MDSs) or myelodysplastic neoplasms, for whom the expected survival can vary from a few months to >10 years. For the past 5 decades, patients with MDS have been classified into higher-risk vs lower-risk disease phenotypes using sequentially developed clinical prognostic scoring systems. Factors such as morphologic dysplasia, clinical hematologic parameters, cytogenetics, and, more recently, mutational information have been captured in prognostic scoring systems that refine risk stratification and guide therapeutic management in patients with MDS. This review describes the progressive evolution and improvement of these systems which has led to the current Molecular International Prognostic Scoring System.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2023 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2023 Type: Article